Research on presence in virtual reality: A survey MJ Schuemie, P Van Der Straaten, M Krijn, CAPG Van Der Mast CyberPsychology & Behavior 4 (2), 183-201, 2001 | 864 | 2001 |
Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia PMG Emmelkamp, M Krijn, AM Hulsbosch, S De Vries, MJ Schuemie, ... Behaviour research and therapy 40 (5), 509-516, 2002 | 506 | 2002 |
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ... Studies in health technology and informatics 216, 574, 2015 | 452 | 2015 |
Treatment of acrophobia in virtual reality: The role of immersion and presence M Krijn, PMG Emmelkamp, R Biemond, CW de Ligny, MJ Schuemie, ... Behaviour research and therapy 42 (2), 229-239, 2004 | 375 | 2004 |
Overview of BioCreative II gene normalization AA Morgan, Z Lu, X Wang, AM Cohen, J Fluck, P Ruch, A Divoli, K Fundel, ... Genome biology 9 (S2), S3, 2008 | 350 | 2008 |
Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project PM Coloma, MJ Schuemie, G Trifiro, R Gini, R Herings, J Hippisley‐Cox, ... Pharmacoepidemiology and drug safety 20 (1), 1-11, 2011 | 283 | 2011 |
The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns L Wijnans, C Lecomte, C de Vries, D Weibel, C Sammon, A Hviid, ... Vaccine 31 (8), 1246-1254, 2013 | 218 | 2013 |
Characterizing treatment pathways at scale using the OHDSI network G Hripcsak, PB Ryan, JD Duke, NH Shah, RW Park, V Huser, MA Suchard, ... Proceedings of the National Academy of Sciences 113 (27), 7329-7336, 2016 | 177 | 2016 |
Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study A Arfè, L Scotti, C Varas-Lorenzo, F Nicotra, A Zambon, B Kollhorst, ... bmj 354, i4857, 2016 | 174 | 2016 |
A dictionary to identify small molecules and drugs in free text KM Hettne, RH Stierum, MJ Schuemie, PJM Hendriksen, ... Bioinformatics 25 (22), 2983-2991, 2009 | 166 | 2009 |
Distribution of information in biomedical abstracts and full-text publications MJ Schuemie, M Weeber, BJA Schijvenaars, EM van Mulligen, ... Bioinformatics 20 (16), 2597-2604, 2004 | 156 | 2004 |
Anni 2.0: a multipurpose text-mining tool for the life sciences R Jelier, MJ Schuemie, A Veldhoven, LCJ Dorssers, G Jenster, JA Kors Genome biology 9 (6), 1-10, 2008 | 154 | 2008 |
Evaluating the impact of database heterogeneity on observational study results D Madigan, PB Ryan, M Schuemie, PE Stang, JM Overhage, ... American journal of epidemiology 178 (4), 645-651, 2013 | 148 | 2013 |
Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapy M Krijn, PMG Emmelkamp, RP Olafsson, M Bouwman, LJ Van Gerwen, ... Aviation, space, and environmental medicine 78 (2), 121-128, 2007 | 133 | 2007 |
Interpreting observational studies: why empirical calibration is needed to correct p‐values MJ Schuemie, PB Ryan, W DuMouchel, MA Suchard, D Madigan Statistics in medicine 33 (2), 209-218, 2014 | 123 | 2014 |
Risk of upper gastrointestinal bleeding from different drug combinations GMC Masclee, VE Valkhoff, PM Coloma, M de Ridder, S Romio, ... Gastroenterology 147 (4), 784-792. e9, 2014 | 118 | 2014 |
Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? G Trifirò, PM Coloma, PR Rijnbeek, S Romio, B Mosseveld, D Weibel, ... Journal of internal medicine 275 (6), 551-561, 2014 | 112 | 2014 |
Word sense disambiguation in the biomedical domain: an overview MJ Schuemie, JA Kors, B Mons Journal of Computational Biology 12 (5), 554-565, 2005 | 111 | 2005 |
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 … PB Ryan, JB Buse, MJ Schuemie, F DeFalco, Z Yuan, PE Stang, JA Berlin, ... Diabetes, Obesity and Metabolism 20 (11), 2585-2597, 2018 | 106 | 2018 |
Defining a reference set to support methodological research in drug safety PB Ryan, MJ Schuemie, E Welebob, J Duke, S Valentine, AG Hartzema Drug safety 36 (1), 33-47, 2013 | 103 | 2013 |